Abstract Body

Background: Since most routine and scalable assays of HIV persistence have sensitivities at or near the level of HIV found in most treated adults, there is intense interest in developing novel methods to characterize viral reservoir during therapy. The host response to residual virus may be a sensitive measure of reservoir size. We quantitatively analyzed the level and distribution of anti-HIV antibody profiles in serum samples of a diverse cohort using Luciferase immunoprecipitation systems (LIPS). Methodology: Using the LIPS assay, antibody responses against nine different recombinant HIV proteins were quantitatively analyzed in uninfected blood donors (n=10), elite controllers (n=10), HIV-infected adult patients (n=9) from before and after several years of ART-induced virologic control (n=9) and in the Berlin patient who was cured following a delta32/delta32 CCR5 stem cell transplant. Heatmap and principal component analysis (PCA) was also used to analyze the antibody data. Results: Quantitative humoral profiling of five, recent serial serum samples collected 51-67 months after the transplant from the Berlin patient revealed no antibodies against p24, matrix, nucleocapsid, integrase, protease and gp120, but persistent albeit low levels of antibodies against reverse transcriptase, tat and gp41. In contrast, antibody levels to these HIV proteins persisted at high and stable levels in most non-controllers and antiretroviral-treated subjects. However, five of the ten elite controllers had low levels of antibodies against matrix, reverse transcriptase, integrase and/or protease. PCA and heatmap analysis revealed that the uninfected blood donors and the Berlin patient clustered together and were in close proximity to the five elite controllers with low anti-HIV antibody levels. Since all ten elite controllers showed similar viral loads (<50 copies/ml), these data also highlight the heterogeneity of anti-HIV antibody responses in the elite controllers. Additionally, three of the ART-treated subjects who demonstrated a decrease in HIV antibodies following treatment showed a shift in their PCA profile closer to the uninfected controls following treatment. Across all proteins, responses to gp41 tended to show the most consistent group-to-group differences, with increasing responses across the uninfected subjects, the Berlin patient, the controllers and the treated group readily apparent. Conclusions: Monitoring the host humoral response to individual HIV proteins, particularly gp41, may provide a practical tool to longitudinally monitor HIV persistence during curative interventions. The mechanism which accounts for uniquely low levels of antibodies towards certain proteins among some controllers is unknown, but may reflect very low reservoirs.